Skip to main content
Premium Trial:

Request an Annual Quote

Phase Genomics OncoTerra Platform

Phase Genomics has launched the OncoTerra platform for precision oncology research. A single assay offers genome-wide detection of a wide range of chromosomal abnormalities without the need for actively dividing cells, high molecular weight DNA extraction, or a high starting volume. The platform is powered by Phase Genomics' ultra-long-range sequencing technology that captures physical proximity data from genomic DNA sequences. These data are then analyzed via proprietary machine learning tools to detect diverse chromosomal aberrations and rearrangements, including tumorigenic rearrangements, that cause and characterize diseases. Phase said the platform is most effective on formalin-fixed paraffin-embedded samples, enabling oncology applications.